 POPULATION: Subjects with chronic HIV-1 infection receiving highly active antiretroviral therapy HAART with HIV RNA levels 50 copiesmL on at least two measurements in the previous 6 months and a CD4 T cell count 400 cellsmm3 within 45 days of study entry will be eligible for this study. 